The 10-day RSI Indicator for GRAL moved out of overbought territory on October 06, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 instances where the indicator moved out of the overbought zone. In 22 of the 22 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GRAL as a result. In 35 of 43 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.
The Moving Average Convergence Divergence Histogram (MACD) for GRAL turned negative on October 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In 17 of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRAL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +16.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRAL advanced for three days, in 107 of 124 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
GRAL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 100 of 107 cases where GRAL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.151) is normal, around the industry mean (63.909). P/E Ratio (-12.634) is within average values for comparable stocks, (1.606). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (18.248) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. GRAL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRAL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NTRA declined for three days, in 205 of 271 cases, the price declined further within the following month. The odds of a continued downward trend are 76%.
The 10-day RSI Indicator for NTRA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 24 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 63%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 73 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 34 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 68%.
NTRA broke above its upper Bollinger Band on September 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 55 cases where NTRA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +4.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 241 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 238 of 286 cases where NTRA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.608) is normal, around the industry mean (63.909). NTRA's P/E Ratio (-295.867) is considerably lower than the industry average of (1.606). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 10 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating fairly steady price growth. NTRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NTRA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 89 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 10 | |
SMR RATING 1..100 | 94 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 89 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| GRAL | NTRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 63% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 81% | 1 day ago 73% |
| MACD ODDS (%) | 1 day ago 85% | 1 day ago 68% |
| TrendWeek ODDS (%) | 1 day ago 78% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| Advances ODDS (%) | 15 days ago 86% | 15 days ago 79% |
| Declines ODDS (%) | 4 days ago 77% | 6 days ago 76% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 69% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 83% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GRAL’s FA Score shows that 0 FA rating(s) are green while NTRA’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GRAL’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
GRAL (@Medical Specialties) experienced а -10.88% price change this week, while NTRA (@Medical Specialties) price change was +0.41% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.01%. For the same industry, the average monthly price growth was -7.30%, and the average quarterly price growth was +34.04%.
GRAL is expected to report earnings on Nov 18, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
A.I.dvisor indicates that over the last year, GRAL has been loosely correlated with PSNL. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if GRAL jumps, then PSNL could also see price increases.
| Ticker / NAME | Correlation To GRAL | 1D Price Change % | ||
|---|---|---|---|---|
| GRAL | 100% | +3.91% | ||
| PSNL - GRAL | 51% Loosely correlated | +1.47% | ||
| ADPT - GRAL | 47% Loosely correlated | -0.29% | ||
| TWST - GRAL | 44% Loosely correlated | +5.29% | ||
| GH - GRAL | 44% Loosely correlated | -0.45% | ||
| NTRA - GRAL | 41% Loosely correlated | +1.52% | ||
More | ||||
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ADPT. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ADPT could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +1.52% | ||
| ADPT - NTRA | 55% Loosely correlated | -0.29% | ||
| NEO - NTRA | 54% Loosely correlated | -1.38% | ||
| GH - NTRA | 53% Loosely correlated | -0.45% | ||
| ISRG - NTRA | 53% Loosely correlated | +1.52% | ||
| TMO - NTRA | 48% Loosely correlated | -1.54% | ||
More | ||||